Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC
Provided By PR Newswire
Last update: Jul 15, 2024
MUMBAI, India and NAPLES, Fla. and SAN DIEGO, July 15, 2024 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced today that it has divested its U.S. Commercial Women's Health Specialty Business to Evofem Biosciences, Inc. (OTCQB: EVFM) (Evofem), a U.S. biopharmaceutical company focused exclusively on Women's Health. Lupin's U.S. Commercial Women's Health Specialty Business is primarily focused on commercializing SOLOSEC® (secnidazole) 2g oral granules. This FDA-approved single-dose antimicrobial agent provides a complete course of therapy for the treatment of bacterial vaginosis (BV) and trichomoniasis, two common sexual health infections.
Read more at prnewswire.comNASDAQ:ADTX (7/14/2025, 12:19:25 PM)
1.2
0 (0%)
Find more stocks in the Stock Screener
ADTX Latest News and Analysis
12 days ago - ChartmillUnusual volume stocks in Wednesday's sessionThe trading volume of these stocks is deviating from the norm in today's session.
18 days ago - ChartmillWhich stocks have an unusual volume on Thursday?Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
19 days ago - ChartmillLet's have a look at the top gainers and losers one hour before the close of the markets of today's session.Intrigued by the market activity one hour before the close of the markets on Wednesday? Uncover the key winners and losers of today's session in our insightful analysis.
